Diamyd Medical Management

Management Kriterienprüfungen 3/4

Diamyd Medical's CEO ist Ulf Hannelius , ernannt in Apr 2016, hat eine Amtszeit von 8.33 Jahren. Die jährliche Gesamtvergütung beträgt SEK3.01M , bestehend aus 70.9% Gehalt und 29.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.24% der Aktien des Unternehmens, im Wert von €377.29K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.6 Jahre bzw. 20.6 Jahre.

Wichtige Informationen

Ulf Hannelius

Geschäftsführender

SEK 3.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	70.9%
Amtszeit als Geschäftsführer	8.4yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	2.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	20.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ulf Hannelius im Vergleich zu den Einnahmen von Diamyd Medical verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
May 31 2024	n/a	n/a	-SEK 140m
Feb 29 2024	n/a	n/a	-SEK 120m
Nov 30 2023	n/a	n/a	-SEK 116m
Aug 31 2023	SEK 3m	SEK 2m	-SEK 116m
May 31 2023	n/a	n/a	-SEK 119m
Feb 28 2023	n/a	n/a	-SEK 115m
Nov 30 2022	n/a	n/a	-SEK 99m
Aug 31 2022	SEK 3m	SEK 2m	-SEK 104m
May 31 2022	n/a	n/a	-SEK 91m
Feb 28 2022	n/a	n/a	-SEK 106m
Nov 30 2021	n/a	n/a	-SEK 83m
Aug 31 2021	SEK 3m	SEK 2m	SEK 60m
May 31 2021	n/a	n/a	SEK 74m
Feb 28 2021	n/a	n/a	SEK 99m
Nov 30 2020	n/a	n/a	SEK 121m
Aug 31 2020	SEK 3m	SEK 2m	SEK 10m
May 31 2020	n/a	n/a	SEK 13m
Feb 29 2020	n/a	n/a	SEK 13m
Nov 30 2019	n/a	n/a	-SEK 35m
Aug 31 2019	SEK 2m	SEK 1m	-SEK 37m
May 31 2019	n/a	n/a	-SEK 38m
Feb 28 2019	n/a	n/a	-SEK 43m
Nov 30 2018	n/a	n/a	-SEK 42m
Aug 31 2018	SEK 2m	SEK 1m	-SEK 44m

Vergütung im Vergleich zum Markt: UlfDie Gesamtvergütung ($USD292.98K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD809.22K).

Entschädigung vs. Einkommen: UlfDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Ulf Hannelius (49 yo)

8.4yrs

Amtszeit

SEK 3,006,000

Vergütung

Mr. Ulf Hannelius, PhD, MBA, has been the Chief Executive Officer of Diamyd Medical AB (publ) since April 11, 2016 and serves as its President. Mr. Hannelius served as an Interim Chief Executive Officer at...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ulf Hannelius	CEO & President	8.4yrs	SEK 3.01m	0.24% SEK 295.6k
Anna Styrud	Chief Financial Officer	no data	keine Daten	0.14% SEK 171.2k
Martina Widman	Chief Operating Officer	2.3yrs	keine Daten	0.013% SEK 15.6k
Anton Lindqvist	Chief Scientific Officer	7yrs	keine Daten	keine Daten
Christoph Nowak	Chief Medical & Business Officer	2.7yrs	keine Daten	0.0095% SEK 11.8k
Maja Johansson	Chief Operating Officer of Manufacturing Site	1.7yrs	keine Daten	0.0025% SEK 3.1k

2.7yrs

Durchschnittliche Betriebszugehörigkeit

46.5yo

Durchschnittliches Alter

Erfahrenes Management: DMNDas Führungsteam des Unternehmens gilt als erfahren (2.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ake Lernmark	Member of the Scientific Advisory Board	28.7yrs	keine Daten	keine Daten
David Leslie	Member of the Scientific Advisory Board	25.7yrs	keine Daten	keine Daten
Daniel Kaufman	Member of the Scientific Advisory Board	28.7yrs	keine Daten	keine Daten
Anders Essen-Möller	Independent Chairman	28.7yrs	SEK 1.06m	3.27% SEK 4.1m
Mark Atkinson	Chairman of Scientific Advisory Board & Independent Director	27.7yrs	SEK 175.00k	0.017% SEK 20.9k
Karin Hehenberger	Independent Director	3.4yrs	SEK 125.00k	0.010% SEK 12.5k
Erik Nerpin	Independent Vice Chairman	12.7yrs	SEK 230.00k	0.059% SEK 73.1k
Torbjörn Bäckström	Independent Director	7.7yrs	SEK 138.00k	0.0010% SEK 1.2k
Maria-Teresa Essen-Möller	Independent Director	15.7yrs	SEK 164.00k	1.37% SEK 1.7m
Karin Rosen	Independent Director	1.5yrs	SEK 28.00k	0.000010% SEK 12.4

20.7yrs

Durchschnittliche Betriebszugehörigkeit

65.5yo

Durchschnittliches Alter

Erfahrener Vorstand: DMNDie Vorstandsmitglieder sind sehr erfahren ( 20.6 ).

Diamyd Medical Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Independent Chairman recently sold €56k worth of stock

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (Publ) Announces Changes of the Board

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Director recently sold €99k worth of stock

Recent updates

Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

New major risk - Share price stability

Third quarter 2024 earnings released

Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024

Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial

Independent Chairman recently sold €56k worth of stock

Recruitment Milestone Reaches in Diamyd® Phase 3 Trial

Second quarter 2024 earnings released

New major risk - Share price stability

First quarter 2024 earnings released

In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production

Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023

Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million.

Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset

Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection

Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024

Full year 2023 earnings released: kr1.30 loss per share (vs kr1.35 loss in FY 2022)

Diamyd Medical AB (Publ) Announces Changes of the Board

Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US

New minor risk - Shareholder dilution

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022)

Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia

Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021)

All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd

Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023

Third quarter 2022 earnings released

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3

Director recently sold €99k worth of stock

Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd

Second quarter 2022 earnings released

Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited

Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe

First quarter 2022 earnings: Revenues miss analyst expectations

Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China

Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes

Director recently sold €358k worth of stock

Investor sentiment deteriorated over the past week

Diamyd Medical Pauses Start of Phase III Trial

Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020)

Investor sentiment deteriorated over the past week

Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd®

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months

the 24-Month Follow-Up of DIAGNODE-2 with the Diabetes Vaccine Diamyd® Will Be Presented in Early July

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released

Diamyd Medical AB (publ) Announces Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd®

Investor sentiment improved over the past week

New 90-day high: €3.62

Investor sentiment improved over the past week

New 90-day low: €2.46

Director recently sold €116k worth of stock

New 90-day low: €2.73

Diamyd Medical AB Announces Positive Safety Evaluation of Remygen® in High Dose and in Combination with Alprazolam Gives the Go-Ahead for the Continuation of the Trial

Meta-Analysis Updated with DIAGNODE-2 Results Provides Further Support for A Precision Medicine Approach Using Diamyd Medical

Diamyd Medical and Critical Path Institute Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes

Insider recently sold €34k worth of stock